<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">82980</article-id><article-id pub-id-type="doi">10.7554/eLife.82980</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Future COVID19 surges prediction based on SARS-CoV-2 mutations surveillance</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-291888"><name><surname>Najar</surname><given-names>Fares Z</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291889"><name><surname>Linde</surname><given-names>Evan</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2053-6721</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291890"><name><surname>Murphy</surname><given-names>Chelsea L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291891"><name><surname>Borin</surname><given-names>Veniamin A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291892"><name><surname>Wang</surname><given-names>Haun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-105903"><name><surname>Haider</surname><given-names>Shozeb</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2650-2925</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-222245"><name><surname>Agarwal</surname><given-names>Pratul K</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3848-9492</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">High-Performance Computing Center</institution>, <institution>Oklahoma State University</institution>, <addr-line><named-content content-type="city">Stillwater</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">School of Pharmacy, Pharmaceutical and Biological Chemistry</institution>, <institution>University College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">1High-Performance Computing Center</institution>, <institution>Oklahoma State University</institution>, <addr-line><named-content content-type="city">Stillwater</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-190571"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing editor</role><aff><institution>DaVita Labs</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>pratul.agarwal@okstate.edu</email> (PA);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>01</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e82980</elocation-id><history><date date-type="received"><day>25</day><month>08</month><year>2022</year></date><date date-type="accepted"><day>18</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Najar et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Najar et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-82980-v1.pdf"/><abstract><p>COVID19 has aptly revealed that airborne viruses such as SARS-CoV-2 with the ability to rapidly mutate, combined with high rates of transmission and fatality can cause a deadly world-wide pandemic in a matter of weeks.<sup>1</sup> Apart from vaccines and post-infection treatment options, strategies for preparedness will be vital in responding to the current and future pandemics. Therefore, there is wide interest in approaches that allow predictions of increase in infections ('surges') before they occur. We describe here real time genomic surveillance particularly based on mutation analysis, of viral proteins as a methodology for <italic>a priori</italic> determination of surge in number of infection cases. The full results are available for SARS-CoV-2 at http://pandemics.okstate.edu/covid19/, and are updated daily as new virus sequences become available. This approach is generic and will also be applicable to other pathogens.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><funding-statement>No external funding was received for this work.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Shozeb Haider, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All sequences used in this work are available from GenBank. The protocol used for analysis are described in the supporting information.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Dennis A Benson</collab><collab>Mark Cavanaugh</collab><collab>Karen Clark</collab><collab>Ilene Karsch-Mizrachi</collab><collab>David J Lipman</collab><collab>James Ostell</collab><collab>Eric W Sayers</collab></person-group><year iso-8601-date="2013">2013</year><source>GenBank</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/genbank/">https://www.ncbi.nlm.nih.gov/genbank/</ext-link><comment>GenBank SARS-CoV-2</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-82980-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>